Name | TA-01 |
---|---|
Synonyms |
Pyridine, 4-[2-(2,6-difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-
4-[2-(2,6-Difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyridine |
Description | TA-01 is a potent CK1 and p38 MAPK inhibitor, with IC50s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively. |
---|---|
Related Catalog | |
Target |
CKIϵ:6.4 nM (IC50) CKIδ:6.8 nM (IC50) p38 MAP kinase:6.7 nM (IC50) |
In Vitro | TA-01 is a potent CK1 and p38 MAPK inhibitor, with IC50s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively. TA-01 (5 μM) is not cytotoxic, completely inhibits cardiogenesis, but induces cardiogenesis at lower concentration[1]. |
Kinase Assay | Compounds (TA-01) are dissolved in DMSO and tested at 10 μM concentrations against a panel of 97 kinases, which are related to stem cell differentiation and cell signaling pathways. Kinome profiling is carried out by kinase profiling service[1]. |
Cell Assay | HES-3, H7 and IPS are harvested and seeded at 1.1 × 106 cells/mL as EBs in ultra-low attachment 12-well plates in bSFS medium: DMEM supplemented with 2 mM l-glutamine, 0.182 mM sodium pyruvate, 1% non-essential amino acids, 0.1 mM β-mercaptoethanol, 5.6 mg/L transferrin, 20 μg/L sodium selenite, 0.25% (w/vol) Bovine Serum Albumin and 0.25% (w/vol) Hysoy. Cells are incubated at 37°C and 5% CO2 to allow EB formation. The medium is refreshed after 1 day and then every 2-3 days. Cells are stimulated with the respective compounds (TA-01) dissolved in DMSO (1 μL DMSO/mL of media) starting from day 1 or day 4, until day 8. CHIR99021 is applied for the first 24 h only[1]. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 511.1±50.0 °C at 760 mmHg |
Molecular Formula | C20H12F3N3 |
Molecular Weight | 351.325 |
Flash Point | 262.9±30.1 °C |
Exact Mass | 351.098328 |
LogP | 4.66 |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.606 |